269 related articles for article (PubMed ID: 8113966)
1. Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/sparteine) polymorphism.
Mikus G; Bochner F; Eichelbaum M; Horak P; Somogyi AA; Spector S
J Pharmacol Exp Ther; 1994 Feb; 268(2):546-51. PubMed ID: 8113966
[TBL] [Abstract][Full Text] [Related]
2. Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans.
Fromm MF; Hofmann U; Griese EU; Mikus G
Clin Pharmacol Ther; 1995 Oct; 58(4):374-82. PubMed ID: 7586928
[TBL] [Abstract][Full Text] [Related]
3. Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers?
Sindrup SH; Poulsen L; Brøsen K; Arendt-Nielsen L; Gram LF
Pain; 1993 Jun; 53(3):335-339. PubMed ID: 8351162
[TBL] [Abstract][Full Text] [Related]
4. The pharmacogenetics of codeine hypoalgesia.
Sindrup SH; Brøsen K
Pharmacogenetics; 1995 Dec; 5(6):335-46. PubMed ID: 8845855
[TBL] [Abstract][Full Text] [Related]
5. Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype.
Mikus G; Trausch B; Rodewald C; Hofmann U; Richter K; Gramatté T; Eichelbaum M
Clin Pharmacol Ther; 1997 Apr; 61(4):459-66. PubMed ID: 9129563
[TBL] [Abstract][Full Text] [Related]
6. Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake.
Sindrup SH; Hofmann U; Asmussen J; Mikus G; Brøsen K; Nielsen F; Ingwersen SH; Broen Christensen C
Eur J Clin Pharmacol; 1996; 49(6):503-9. PubMed ID: 8706777
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions.
Caraco Y; Sheller J; Wood AJ
J Pharmacol Exp Ther; 1996 Sep; 278(3):1165-74. PubMed ID: 8819499
[TBL] [Abstract][Full Text] [Related]
8. The influence of pharmacogenetics on opioid analgesia: studies with codeine and oxycodone in the Sprague-Dawley/Dark Agouti rat model.
Cleary J; Mikus G; Somogyi A; Bochner F
J Pharmacol Exp Ther; 1994 Dec; 271(3):1528-34. PubMed ID: 7996467
[TBL] [Abstract][Full Text] [Related]
9. Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI).
Dayer P; Desmeules J; Leemann T; Striberni R
Biochem Biophys Res Commun; 1988 Apr; 152(1):411-6. PubMed ID: 3358767
[TBL] [Abstract][Full Text] [Related]
10. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.
Kévorkian JP; Michel C; Hofmann U; Jacqz-Aigrain E; Kroemer HK; Peraldi MN; Eichelbaum M; Jaillon P; Funck-Brentano C
Clin Pharmacol Ther; 1996 May; 59(5):583-92. PubMed ID: 8646830
[TBL] [Abstract][Full Text] [Related]
11. Patient-controlled analgesia (PCA) with codeine for postoperative pain relief in ten extensive metabolisers and one poor metaboliser of dextromethorphan.
Persson K; Sjöström S; Sigurdardottir I; Molnár V; Hammarlund-Udenaes M; Rane A
Br J Clin Pharmacol; 1995 Feb; 39(2):182-6. PubMed ID: 7742159
[TBL] [Abstract][Full Text] [Related]
12. CYP2D6-debrisoquine hydroxylase gene polymorphism in multiple system atrophy.
Planté-Bordeneuve V; Bandmann O; Wenning G; Quinn NP; Daniel SE; Harding AE
Mov Disord; 1995 May; 10(3):277-8. PubMed ID: 7651442
[TBL] [Abstract][Full Text] [Related]
13. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation.
Eckhardt K; Li S; Ammon S; Schänzle G; Mikus G; Eichelbaum M
Pain; 1998 May; 76(1-2):27-33. PubMed ID: 9696456
[TBL] [Abstract][Full Text] [Related]
14. A Single Site Population Study to Investigate CYP2D6 Phenotype of Patients with Persistent Non-Malignant Pain.
Radford H; Simpson KH; Rogerson S; Johnson MI
Medicina (Kaunas); 2019 May; 55(6):. PubMed ID: 31141989
[No Abstract] [Full Text] [Related]
15. Role of polymorphic debrisoquin 4-hydroxylase activity in the stereoselective disposition of mexiletine in humans.
Abolfathi Z; Fiset C; Gilbert M; Moerike K; Bélanger PM; Turgeon J
J Pharmacol Exp Ther; 1993 Sep; 266(3):1196-201. PubMed ID: 8371133
[TBL] [Abstract][Full Text] [Related]
16. Thebaine O-demethylation to oripavine: genetic differences between two rat strains.
Mikus G; Somogyi AA; Bochner F; Eichelbaum M
Xenobiotica; 1991 Nov; 21(11):1501-9. PubMed ID: 1763524
[TBL] [Abstract][Full Text] [Related]
17. The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism.
Ebner T; Eichelbaum M
Br J Clin Pharmacol; 1993 Apr; 35(4):426-30. PubMed ID: 8485023
[TBL] [Abstract][Full Text] [Related]
18. Impact of environmental and genetic factors on codeine analgesia.
Desmeules J; Gascon MP; Dayer P; Magistris M
Eur J Clin Pharmacol; 1991; 41(1):23-6. PubMed ID: 1782973
[TBL] [Abstract][Full Text] [Related]
19. Codeine analgesia is due to codeine-6-glucuronide, not morphine.
Vree TB; van Dongen RT; Koopman-Kimenai PM
Int J Clin Pract; 2000; 54(6):395-8. PubMed ID: 11092114
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
